YOLFTbeta
Jasper Therapeutics Inc

Jasper Therapeutics Inc

JSPR · NASDAQ · Healthcare / Biotechnology

13.68USD+0.31 (+2.32%)

Price History

Full chart

Market Stats

Previous Close13.37
Open13.51
Day Range12.93 – 14.56
52-Week Range0.315 – 2.69
Volume16.49K
Market Cap20.27M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.93
Dividend Yield0.00%
Beta3.04
50-Day Avg0.7008
200-Day Avg1.01

About

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jeetinder Singh Mahal M.B.A.
  • Employees22
  • Headquarters2200 Bridge Pkwy, Redwood City, CA, United States, 94065, USA
  • Websitehttps://jaspertx.com

Leadership

  • Mr. Thomas G. WiggansExecutive Chairman · b. 1952
  • Mr. Jeetinder Singh Mahal M.B.A.President, CEO & Director · b. 1972
  • Dr. Judith Anne Shizuru M.D., Ph.D.Co-Founder, Member of Scientific Advisory Board & Director · b. 1956
  • Mr. Herbert C. Cross CPACFO & Corporate Secretary · b. 1972
  • Mr. Matthew E. RosChief Operating Officer · b. 1967
  • Alex GrayHead of Investor Relations
  • Mr. Matthew FordSenior Vice President of Human Resources
  • Dr. Gregory F. Keenan M.D.Chief Medical Officer · b. 1961
  • Dr. Wenru Song M.D., Ph.D.Executive VP and Head of R&D

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-06.20M13.51M000
Growth (%)---+118.06%-100.00%--
Cost of Revenue-21.00K566.00K1.31M1.11M1.37M1.06M
Gross Profit--21.00K-566.00K-1.31M-1.11M-1.37M-1.06M
Gross Margin---9.13%-9.70%---
Operating Expense-20.66M36.27M49.89M67.75M74.87M79.46M
Operating Income-4.71M-20.68M-36.83M-51.20M-68.86M-76.24M-80.52M
Operating Margin---594.46%-378.92%---
EBITDA-277.00K-31.95M-30.26M-36.71M-63.36M-69.90M-74.75M
EBITDA Margin---488.38%-271.70%---
Net Income-4.99M-31.67M-30.64M-37.69M-64.47M-71.27M-75.80M
Net Income Margin---494.46%-278.92%---
R&D3.62M15.88M25.42M34.63M51.78M55.82M60.52M
R&D as % of Total Revenue--410.28%256.29%---
Interest Expense010.99M6.20M13.51M---
Interest Expense % of Total Revenue--100.00%100.00%---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.21M23.36M93.65M48.36M94.89M79.90M35.78M
Total Liabilities6.11M58.49M24.14M12.37M16.45M18.23M31.63M
Total Equity21.10M-35.13M69.52M35.99M78.44M61.67M4.15M
Cash27.16M19.84M84.70M38.25M86.89M71.64M28.69M
Total Debt-1.62M2.88M3.65M2.79M1.81M1.24M
Net Debt-27.16M-18.21M-81.82M-34.60M-84.10M-69.82M-27.46M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.97M-18.27M-33.68M-45.86M-52.07M-62.60M-77.16M
Investing Cash Flow-2.43M198.34K-2.43M-576.00K-267.00K-532.00K5.00K
Financing Cash Flow29.13M11.29M100.97M55.00K100.97M47.88M34.21M
Capital Expenditure2.43M2.43M2.43M576.00K267.00K552.00K7.00K
Free Cash Flow-1.97M-18.27M-36.11M-46.43M-52.33M-63.15M-77.17M
FCF to OCF100.00%100.00%107.21%101.26%100.51%100.88%100.01%

Earnings

Report DateNov 20, 2019Mar 26, 2020May 13, 2020Aug 14, 2020Nov 10, 2020Mar 30, 2021May 24, 2021Aug 16, 2021Nov 12, 2021Mar 18, 2022May 12, 2022Aug 12, 2022Nov 10, 2022Mar 8, 2023May 12, 2023Aug 11, 2023Nov 9, 2023Mar 4, 2024May 14, 2024Aug 13, 2024Nov 7, 2024Feb 27, 2025May 12, 2025Aug 13, 2025Nov 10, 2025Dec 31, 2025May 14, 2026Aug 14, 2026Nov 9, 2026
EPS Estimate-0.00-------2.70-0.34-3.40-3.60-3.70-0.36-1.50-1.47-1.50-1.57-1.23-1.12-1.08-1.23-1.48-1.33-1.21-0.82-0.54-0.37-0.08
EPS Actual-0.000.000.11-0.02-0.02-0.010.44-1.31-2.67-0.79-3.54-2.45-3.20-0.36-1.47-1.51-1.63-1.50-1.03-0.97-1.24-1.62-1.41-1.74-1.13-0.54-0.38-0.24-
Surprise--------1.11%-132.35%-4.12%31.94%13.51%0.00%2.00%-2.72%-8.67%4.46%16.26%13.39%-14.81%-31.71%4.50%-30.83%6.61%33.82%29.63%35.14%-
Timing-----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-After-hoursPre-market-

Key Statistics & Ratios

Market Cap20.27M
Enterprise Value11.82M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book14.67
EPS-0.93
Book Value0.05
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-52.30M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-255.05%
Return on Assets-113.41%
Shares Outstanding33.27M
Shares Float30.01M
Beta3.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 7.38
  • Strong Buy
    7
  • Buy
    4

Ownership Breakdown

Institutions
39.43%
Insiders
2.87%
Retail / Other
57.70%

Top Institutional Holders

  • Velan Capital Investment Management LP
    2.67M8.02%
  • Kingdon Capital Management LLC
    1.35M4.06%
  • Morgan Stanley - Brokerage Accounts
    1.33M4.01%
  • Vanguard Capital Management, LLC
    1.17M3.52%
  • Rock Springs Capital Management LP
    1.10M3.31%
  • The Carlyle Group Inc
    1.07M3.20%
  • BOOTHBAY FUND MANAGEMENT, LLC
    582.75K1.75%
  • GSA Capital Partners LLP
    534.70K1.61%
  • Millennium Management LLC
    486.93K1.46%
  • Lion Point Capital, LP
    465.00K1.40%
  • Jacobs Levy Equity Management, Inc.
    322.27K0.97%
  • Geode Capital Management, LLC
    317.68K0.95%
  • Bank of America Corp
    293.26K0.88%
  • BlackRock Inc
    242.06K0.73%
  • Renaissance Technologies Corp
    177.50K0.53%
  • Vanguard Fiduciary Trust Co
    149.94K0.45%
  • ADAR1 Capital Management LLC
    140.00K0.42%
  • Quarry LP
    131.53K0.40%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    833.39K2.50%
  • Fidelity Extended Market Index
    127.53K0.38%

Stock Splits

  • Nov 6, 20261:30
  • Jan 4, 20241:10